Cancer cells impair monocyte-mediated T-cell activation by disrupting inflammatory pathways in the tumor microenvironment.

Recent advances in immunotherapy research have revealed crucial roles for new immune cells in combating cancer, leading to ...

Delve into the expanding and diverse field of cancer vaccines with various approaches exploiting the immune system to fight ...

Fibroblastic reticular cells (FRCs) create T-cell-supportive niches within lung cancer tumors, facilitating T-cell migration, ...

MSCs hold great promise as a therapeutic tool in cancer immunotherapy due to their immunomodulatory properties, tumor-homing ...

A study from the University of Michigan Health Rogel Cancer Center may have—at last—cracked the cold case of immunotherapy ...

University of Michigan researchers identified UBA1 as a key player in immunotherapy resistance. Inhibiting UBA1 boosts T-cell ...

Prostate cancer and other cancers characterized by “cold” tumors could become more responsive to checkpoint blockade if UBA1 is inhibited.

T-cells, part of the immune system, can kill cancer cells ... Both T-cells and CAR-T cells can become "exhausted" in the ...

A recent study reveals that immunosuppression, or reduced immune response, in prostate cancer is associated with a ...

Tumor cells transform fibroblasts into cancer-associated fibroblasts, which have an important immunosuppressive activity on which growth, invasion, and metastasis depend. These activated fibroblasts ...

In recent decades, immunotherapy has transformed cancer treatment, offering effective options for diseases once considered ...